PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Baumhoer, D. ; Smida, J. ; Specht, K.* ; Bink, K. ; Quintanilla-Martinez, L. ; Rosemann, M. ; Siggelkow, H.* ; Nathrath, W.B.* ; Atkinson, M.J. ; Bielack, S.* ; Jundt, G.* ; Nathrath, M.

Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma.

Hum. Pathol. 42, 859-866 (2011)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Human epidermal growth factor receptor 2 expression in osteosarcoma and its relationship to prognosis have been the subject of several conflicting reports, most of them relying on immunohistochemical studies. Because the urgent need of prognostic markers and effective new treatment options for osteosarcoma patients, we evaluated the role of human epidermal growth factor receptor 2 in 2 well-characterized sets of pretherapeutic osteosarcoma samples (46 paraffin-embedded and 46 fresh-frozen biopsy samples) using immunohistochemistry with 2 different antibodies [DAKO A0485 (Glostrup, Denmark) and Novocastra CB11 (Newcastle, UK)] as well as fluorescence in situ hybridization, real-time polymerase chain reaction, and SNP array analyses and correlated our findings with clinicopathological parameters. However, our study failed to detect unequivocal evidence of human epidermal growth factor receptor 2 gene amplification or overexpression of human epidermal growth factor receptor 2 messenger RNA or protein in any of the investigated tumors. Only in a small subset of samples, a moderate increase in messenger RNA levels (13.6%) or focal membranous immunoreactivity (8.7%; A0485) was detected but did not correlate with survival or response to chemotherapy. Cytoplasmic staining was identified more frequently (63%; CB11) but again did not show any association with clinicopathological parameters. In conclusion, our study does not support a role for human epidermal growth factor receptor 2 as a prognostic marker in osteosarcoma.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
2.998
1.410
3
3
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Osteosarcoma; HER-2/neu; ERBB2; FISH; Immunohistochemistry; qRT-PCR; Single nucleotide polymorphism (SNP) array
Sprache
Veröffentlichungsjahr 2011
HGF-Berichtsjahr 2011
ISSN (print) / ISBN 0046-8177
e-ISSN 1532-8392
Zeitschrift Human Pathology
Quellenangaben Band: 42, Heft: 6, Seiten: 859-866 Artikelnummer: , Supplement: ,
Verlag Elsevier
Begutachtungsstatus Peer reviewed
Institut(e) CCG Osteosarcoma (PATH-KOS)
Institute of Pathology (PATH)
Institute of Radiation Biology (ISB)
POF Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
30202 - Environmental Health
Forschungsfeld(er) Enabling and Novel Technologies
Radiation Sciences
PSP-Element(e) G-520800-001
G-500300-001
G-500200-001
PubMed ID 21292304
DOI 10.1016/j.humpath.2010.09.016
Scopus ID 79956125778
Erfassungsdatum 2011-07-22
[➜Korrektur melden]